Supportive Oligonucleotide Therapy (SOT)

Supportive Oligonucleotide Therapy (SOT) goes by many names. It is sometimes called “Short Oligonucleotide Treatment” or “Anti-Sense Oligonucleotide Technique” (AOT), or “Gene- Silencing Therapy.”

“Oligo” means “few” in Greek. A nucleotide is the basic building block of nucleic acid, which forms the backbone of DNA. Oligonucleotides are basically short, single-strand DNA codes. The creation of a specific synthetic oligonucleotide intended to bind to its genetic counterpart in the body is called an “antisense oligonucleotide.”

The first experiment in anti-sense technology took place in 1978. Since then, 6 different anti- sense treatments have been approved by the FDA. In the U.S., Hepatitis C is now cured using an FDA-approved anti-sense technology. Most Hepatitis C patients can be cured with only one treatment, so researchers have high hopes for other diseases as well.

Specifically, Supportive Oligonucleotide Therapy is one form of AOT that is not yet FDA approved. However, over the last few years, SOT use has skyrocketed. SOT is a cutting-edge, promising new treatment for cancer, Lyme, bacterial infections, and certain viruses such as Herpes and Epstein-Barr. Although results cannot be guaranteed, the past few years of clinical experience have shown that symptoms of these diseases can be greatly diminished or eliminated.

In layman’s terms, Supportive Oligonucleotide Therapy is the creation of tiny “keys” that precisely fit into chosen “locks” inside the patient’s body. Think of the locks as specific sections of DNA inside each cell that are perpetuating disease. The keys are short sections of information that are designed to fit into each and every lock, breaking apart the information codes that allow for the continuation of that disease.

Inside your body, messenger RNA (mRNAͿ acts as a go-between), so that your DNA can control protein production. During a process called transcription, mRNA is made in the mirror image of DNA, and then leaves the cell wall to be translated into protein. Think of mRNA as the genetic template of DNA, on a mission to carry out DNA’s instructions, since DNA is not allowed to leave the nucleus of the cell.

Supportive Oligonucleotide Technique (SOT) works by shutting down gene replication of harmful messenger RNA sequences in cancer cells. What follows is “apoptosis” or programmed cell death of cancer cells, viruses, infections, or pathogens, destroying their life cycles. Harmful effects of cancer and pathogens are largely due to their rampant growth and activity. SOT prevents gene replication of these unwanted cells, so their numbers steadily shrink over time.

Each SOT molecule attacks a specific target by blocking the expression and transcription of one gene only. After it has done its job, the complementary mRNA then releases the SOT molecule so that it moves on to the next target with the same sequence. Hence, one molecule of SOT can be re-engaged again and again to cause death to thousands of cancer cells, infections, viruses, or Lyme bacteria.

Each SOT “soldier” is created to be highly specific and will only work for the patient that it was made for. Upon injection into the bloodstream, they will break apart each defective sense strand, one by one. (Hence the term “anti-sense.”)

SOT infusions will not interfere with the genetics of human cells. Cell death only affects harmful infections and viruses. SOT is not gene manipulation, gene splicing, or gene insertion. Nor is it technically a drug since the contents of the infusion are created from the patient’s own blood. SOT will not negatively affect a patient’s immune system, nor does it alter his/her DNA, normal organs, tissues, or cells in any way.

This short, 3-minute video on YouTube explains the basic mechanics of how anti-sense treatments work:

Supportive Oligonucleotide Technique (SOT) is effective against Circulating Tumor Cells (CTCs), Cancer Stem Cells (CSCs), Primary Tumor Cells, Human Immunodeficiency Virus (HIV), and Metastatic Tumors.

SOT cannot be used in cases of encapsulated cancers, such as tumors of the brain, due to a lack of circulating cancer cells in the blood. Also, SOT may not be used to treat large or advanced tumors due to a risk of developing Tumor Lysis Syndrome or “TLS.” TLS is a rare occurrence and the patient is carefully monitored for this to occur.

Supportive Oligonucleotide Therapy (SOT) may be repeated up to three times per year if desired. However, before each new treatment, it is recommended that the patient test again for the presence of circulating tumor cells or pathogens. The goal, of course, is the complete eradication of cancer or infection over time. In the past 5 years, thousands of people have been treated with SOT in the U.S. and around the world with incredible success.

To accurately gauge the body’s response to Supportive Oligonucleotide Therapy (SOT) treatments, a test called “PrimeSpot” is available through RGCCs affiliate lab, Biocentaur, in the United Kingdom. This test is only for patients suffering from Lyme or viral infections and cannot be used for cancer patients.

If a patient has multiple active infections, multiple SOT treatments will be needed to treat each separate infection. The response to Supportive Oligonucleotide Therapy (SOT) varies, depending on the overall health of the patient, and the severity of his/her condition. Some patients are cured of symptoms in one treatment and others require two or more treatments to settle into a quiet remission.

If you’re interested in the possibility of trying SOT, book a consultation with Jennifer Baer at our front desk. Jennifer will sit down with you in a one-on-one appointment to review your medical history, most recent test results, and answer any questions you may have. She will determine whether you are a good candidate for SOT and order additional labs if necessary.

To begin SOT treatment, one of the nurses at Horizons of Health will do a blood draw and mail the sample to an RGCC lab. Once the lab receives the patient’s blood, RGCC scientists will identify the specific gene sequences that are perpetuating cancer, Lyme, or virus. Using an international database, they will cross-reference specific gene sequences to create an intravenous infusion that is 98% specific to the patient’s genes. Each infusion is as unique as the patient’s fingerprint.

Replication genes are sometimes called “sense strands.” Sense strands are genetic codes that allow disease-causing pathogens and cells to replicate and invade the body. RGCC creates an “anti-copy” or mirror image of the replication sequences using a sense strand of nucleic acid, which is then surrounded with synthetic messenger RNA so that it has the ability to penetrate cell walls. Anywhere from 500 million to 1 billion copies of the patient’s unique “mirror images” are created. Then, these molecules are packaged and mailed to our office where you will receive them via IV. SOT administration induces rapid apoptosis which will shut down the gene replication sequences of the target cancer cells, and therefore eliminate the next lifecycle of the pathogens.

The life span of the oligonucleotides is boosted by a proprietary technique, which makes them unrecognizable to the human enzymes that normally break down oligonucleotides. RGCC has found a way to preserve the solubility of the oligonucleotides as well as their ability to penetrate cell membranes. RGCC’s SOT molecules are hardy, and travel everywhere in the body, including through the patient’s blood/brain barrier.

SOT treatment can be administered as an IV, and works up to six months in the body. Conventional treatment strategies of intravenous antihistamines (Famotidine) and low-dose steroids (Dexamethasone) will be given just before the SOT IV begins. These medications help to lessen the already very rare chance of an allergic reaction, and to tighten the vein walls, respectively.

Many Viruses, including:

Usually, side effects on gene silencing therapies are minimal. Some patients experience mild bruising, swelling, or tenderness from the IV needle, which subsides within a day or two.

Longer and more systemic side effects often occur because SOT causes cancer cells and other pathogens to die. This “apoptosis,” also known as cell death, can lead to a Herx-Heimer reaction.

The Herxheimer reaction, often referred to as "herxing," occurs when toxins from dying bacteria or pathogens are released faster than the body can handle them, leading to temporary exacerbation of symptoms.

The patient may feel sluggish, achy, nauseous, and/or run a temperature (generally less than 101˚F) due to a large number of dead or dying pathogens in the body.

Headaches, body aches, exhaustion, diarrhea, mild cough, or other flu-like symptoms are normal and a sign that the treatment is working.

These side effects typically last anywhere from two days to two weeks. Some patients may feel worse for up to a month after SOT, but almost all have reported a tremendous “payoff” after the uncomfortable symptoms resolved.

More serious risks of SOT infusion can occur in cancer patients who have large tumor burdens. Malignant cell death can produce a large amount of dead cellular debris, which can lead to a condition known as Tumor Lysis Syndrome. (This condition is a risk for patients undergoing chemotherapy and radiation as well.) Dying cells release large amounts of potassium, phosphate, and uric acid into the blood.

This can cause heart or kidney problems only in extreme cases. Supportive Oligonucleotide Technique (SOT) is a healing protocol that can be used in conjunction with all other therapies, except for chemotherapy and radiation.

Rest assured, you will be carefully monitored and evaluated throughout your treatment at Horizons of Health to address any adverse effects that may occur.

TLS is a rare occurrence and the patient is carefully monitored for this to occur.

If Tumor Lysis Syndrome (TLS) is a risk, a smaller or weaker dose of SOT can be given to be sure that the patient will tolerate treatment.

TLS is not an issue for those using SOT to heal infections from Lyme or other viruses.

Supportive Oligonucleotide Therapy (SOT) may be repeated up to three times per year if desired. However, before each new treatment, it is recommended that the patient test again for the presence of circulating tumor cells or pathogens.

The goal, of course, is the complete eradication of cancer or infection over time. In the past 5 years, thousands of people have been treated with SOT in the U.S. and around the world with incredible success.

To accurately gauge the body’s response to Supportive Oligonucleotide Therapy (SOT) treatments, a test called “PrimeSpot” is available through RGCCs affiliate lab, Biocentaur, in the United Kingdom. This test is only for patients suffering from Lyme or viral infections and cannot be used for cancer patients.

If a patient has multiple active infections, multiple SOT treatments will be needed to treat each separate infection. The response to Supportive Oligonucleotide Therapy (SOT) varies, depending on the overall health of the patient, and the severity of his/her condition.

Some patients are cured of symptoms in one treatment and others require two or more treatments to settle into a quiet remission.

There is also a facebook group of like-minded individuals who have tried Supportive Oligonucleotide Therapy (SOT) that you may consider joining.

A SOT injection will be given during your visit to Horizons of Health, so if your current health plan covers visits to this office, a small percentage of the total cost of SOT may be covered, please first check with your provider.

Some inclusive health plans allow coverage that can be applied to naturopathic treatments.

We recommend contacting your insurance provider directly prior to finding out if a portion of the cost may be covered.

If you are in the Albany, NY, or nearby regions and are interested in SOT treatment contact us to start transformative journey towards improved health and vitality.

Horizons of Health, we are committed to helping you unlock your body's incredible self-healing potential so feel free to set up a call to learn about our programs and other therapies to help you meet your health goals.

Do you have questions about starting your path back to health? Our patient coordinator is standing by, happy to answer any questions you have to determine if our approach is right for you.